Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.

The American journal of gastroenterology - 1 Dec 2016

Barber Grant E, Yajnik Vijay, Khalili Hamed, Giallourakis Cosmas, Garber John, Xavier Ramnik, Ananthakrishnan Ashwin N

Abstract excerpt

OBJECTIVES: One-fifth of patients with Crohn's disease (CD) are primary non-responders to anti-tumor necrosis factor (anti-TNF) therapy, and an estimated 10-15% will fail therapy annually. Little is known about the genetics of response to anti-TNF therapy. The aim of our study was to identify genetic factors associated with primary non-response (PNR) and loss of response to anti-TNFs in CD. METHODS: From a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Anti-Inflammatory Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crohn Disease

Share to Gastrointestinal Agents

Share to Immunosuppressive Agents

Share to Infliximab

Share to Pharmacogenomic Variants

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 27596696
DOI: 10.1038/ajg.2016.408
PMCID: PMC5143156

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.PMID 27596696Read ↗

Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.Semantic proximity Read ↗

Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn’s Disease Using Transcriptome Imputed from GenotypesSemantic proximity Read ↗

Genetic association of primary non-response to Anti-TNFα therapy in patients with Inflammatory Bowel DiseaseSemantic proximity Read ↗

Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.Semantic proximity Read ↗

The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Genetic risk profiling and prediction of disease course in Crohn's disease patients.Semantic proximity Read ↗

Genetic and genomic predictors of anti-TNF response.Semantic proximity Read ↗

The genetics of IBD : from susceptibility to drug response and patient outcomeSemantic proximity Read ↗

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.Semantic proximity Read ↗

Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease.Semantic proximity Read ↗

DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease.Semantic proximity Read ↗

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.